Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://jonasymhk931290.activosblog.com/41297330/this-new-drug-retatrutide-australia-a-potential-solution-for-weight-management